CNBC Television published this video item, entitled “SVB Leerink: This “holy grail” of the vaccine industry could be worth $10 billion” – below is their description.
Geoffrey Porges, SVB Leerink Director of Therapeutics Research and Senior Biotechnology Analyst, joins Worldwide Exchange to discuss his latest note on the RSV vaccine development industry.
CNBC Television YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.